PHusis Therapeutics Management Team

D. Lynn Kirkpatrick, PHD
President and CEO
Former Co-founder of ProlX Pharmaceuticals and Professor of Chemistry and Biochemistry at the University of Regina, Canada, Lynn Kirkpatrick has spent over 30 years in cancer drug discovery and development. From 1999 to 2006 Dr. Kirkpatrick was CEO of ProlX Pharmaceuticals, taking three small molecules from bench to bedside. When ProlX was acquired by Biomira Inc., a publicly traded company, she became the Chief Scientific Officer of the merged company which changed its name to Oncothyreon, Inc. in 2007. Following her resignation from Oncothyreon in 2009, Dr. Kirkpatrick co-founded PHusis Therapeutics with Drs. Powis, Meuillet and Zhang. Dr. Kirkpatrick received her PhD from the University of Saskatchewan and did post-doctoral research at Yale University School of Medicine. She has published extensively in the area of targeted cancer drug discovery and development with over 120 papers and presentaions and holds numerous patents for novel cancer drugs.

Ms. Berenjian has over twenty years of experience as controller and financial analyst in small companies in Southern California. She has been involved with companies in all stages of development, and has managed all aspects of accounting for a compliance banking company. She has co-ordinated diligence activities for companies undergoing acquisition, supervising audits and overseeing the transition of accounting policies into new company.

Dr. Powis is the Director of the NCI Designated Research Cancer Center at the Sanford Burnham Medical Research Institute (SBMRI) in San Diego California. Former Chair of Experimental Therapeutics and Director of the Center for Targeted Therapy at The University of Texas M. D. Anderson Cancer Center, Dr. Powis is a leader in the field of signal transduction and has extensive experience in the development of anticancer drugs that act against cell signaling pathways including those involving PH domain regulated proteins. Dr. Powis has over 350 publications, and books, 12 patents and has been involved in the development of three anti-cancer agents that are now in clinical development.

Dr. Meuillet, Associate Research Professor, Departments of Nutritional Sciences and Molecular and Cellular Biology, at the University of Arizona Comprehensive Cancer Center, received her Ph.D. in Biochemistry and Pharmacology from the University Louis Pasteur, France. She completed post-doctoral training at the Children’s Memorial Hospital at Northwestern University, Chicago and at the Arizona Comprehensive Cancer Center, Tucson. She has coauthored over 50 papers in the field of cellular signaling and lipidology and studies the process of inflammation, a driving force of cancer metastasis.

Dr. Shuxing Zhang, Assistant Professor, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, obtained his Ph.D. in computational and medicinal chemistry from the University of North Carolina at Chapel Hill. With more than ten years industrial and academic experience in computational drug discovery and development, Dr. Zhang has broad experience in medicinal chemistry, biophysics and computational biology. He has been involved in cancer therapeutics design against numerous protein targets using cutting-edge cheminformatics, bioinformatics and systems biology integrated platforms for molecular interaction pathway analysis, lead identification/optimization, and ADMET studies. His research has earned him the American Chemical Society 2008 Hewlett-Packard Outstanding Scholar Award.

instagram followers audit prada sweatsuit men's brands outlet online instagram anonymous followers tods shoes outlet prada lingerie red prada hat night of the puffings cork board sheet followers gratis instagram analyze instagram followers prada pr 21xs vinyl building materials prada outlet locations night of the pufflings story prada aftershave prada patent loafer prada baguette prada calzature uomo gaining instagram followers chatgpt video prada bag cost prada candy sephora roll of cork rambutan sugar content gucci brands women's clothing outlets online dr patel house tampa instagram glitch followers prada platforms shoes openapi chatgpt instagram followers stuck chatgpt watermark william chicken night of the demons nude amazon prada bag handbag outlet online ferragamo outlet store online chatgpt integration prada sunglasses star prada chunky shoes chatgpt google sheets instagram 50k followers designer sunglasses outlet online carlucci's rosemont used prada loafers make wigs prada law prada bracelet charms fish on bait company white goatee beard gucci fr chatgpt app中文 cardinal materials yacht hat prada official website instagram non followers belle & bloom prada denim tote prada aus prada pattern gucci uae גוצ י prada bags original black prada clutch prada brown boot ugg discount outlets ember fine jewelry prada water splash carlucci chicago lentes prada originales pin board for wall prada backpack purse airbrush effects better than chatgpt prada eyeglasses black gucci website usa jazztrax catalina 2016 yacht club uniforms inside prada bag chatgpt slow roofing supply st louis mo pr17ws prada christian dior outlet online tamagachipatel high school large pin boards gucxi designer brand outlet usa cleaning instagram followers ranbutan meundies boxer prada luna black prada green dress tales of chivalry fallout prada chess set gucci things ladies prada sunglasses prada gold purse bag prada prada triangle perfume prada crystal skirt online outlet store cork board wall outlet department store hernan prada prada robe rihanna instagram followers prada sizing chatgpt api github stuart weitzman shoes outlet gucci italy price prada eyeglasses black gucci l chatgpt developer mode chatgpt vs bing

Board Members


Biotechnology Consultant. Dr. Trown, a seasoned biopharmaceutical executive, held senior positions in preclinical and product development at Lederle Laboratories, Hoffmann-La Roche, Xoma, and Onyx Pharmaceuticals. Dr. Trown focus is small emerging companies and he has a wealth of experience in positioning of new agents for clinical use.

CEO of Viventia Bio Inc.
Former CEO Merchant & Investment Banking, Burrill & Company, Mr. Hurly served investment banking needs of businesses in the healthcare, biotechnology and pharmaceutical sectors. Steve has more than 15 years experience having served as: Managing Director, Investment Banking, Boenning & Scattergood, Inc. Managing Director/Head of the Health Care Group at Janney Montgomery Scott, LLC.Hambrecht & Quist and JP Morgan in San Francisco.

Dr. Chaplin is former Chief Scientific Officer of OXiGENE where he guided lead agent ZYBRESTAT from discovery to Phase III trials and OXi4503 into Phase I. At OXiGENE he developed productive international drug discovery and research collaborations with numerous academic institutions in the USA, Canada and Europe and was closely involved in five financings raising over 200 million dollars. Prior to that Dr. Chaplin oversaw integration of worldwide oncology research operations following merger of RPR and HMR to form AVENTIS and was responsible for their Global Oncology research operations covering discovery through end of Phase I. Additionally he co-founded Angiogene Pharmaceuticals and licensed its lead agent to AstraZeneca.

Dr. Kramer is former Vice President and Head of Discovery for Oncology Therapeutics at Janssen Research & Development, LLC. He was responsible for leading Global Discovery, focusing on aberrant signaling cascades in tumor cells, as well as epigenetic reprogramming and tumor immunology using both small molecule and protein-based large molecule approaches. Dr. Kramer joined Janssen Research & Development from Bristol-Myers Squibb (BMS), where he was VP Drug Discovery and Research site head in Princeton, NJ where he provided scientific leadership and strategic oversight for many preclinical Oncology and Immunology programs/projects that entered development, several of which have gone on to receive regulatory approvals for treating patients with chronic myeloid leukemia, breast cancer and melanoma.